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Brief Report
A Method to Improve Continuous Renal Replacement 
Therapy Circuit Survival Time in Critically Ill Coronavirus 
Disease 2019 Patients With Acute Kidney Injury
Meint Volbeda, MD1; Mark Londema, MD1; Matijs van Meurs, MD, PhD1; Coen A. Stegeman, MD, PhD2;  
Ron T. Gansevoort, MD, PhD2; Stefan P. Berger, MD, PhD2; Peter H. J. van der Voort, MD, PhD1;  
Casper F. M. Franssen, MD, PhD2
Objectives: Optimizing continuous renal replacement therapy circuit 
survival in coronavirus disease 2019 patients admitted to the ICU.
Design: Single-center prospective observational cohort study.
Setting: Tertiary academic teaching ICU.
Patients: Between March 19, 2020, and May 18, 2020, 11 out of 
101 coronavirus disease 2019 patients were treated with continuous 
renal replacement therapy comprising 127 continuous renal replace-
ment therapy days.
Interventions: A nonrandomized observational comparison of circuit 
anticoagulation modalities using standard regional citrate anticoagu-
lation, continuous IV heparin anticoagulation, or the combination of 
regional citrate anticoagulation with either continuous IV heparin or 
therapeutic dose nadroparin.
Measurements and Main Results: Circuit patency was shorter than 
24 hours using standard regional citrate anticoagulation or continu-
ous IV heparin anticoagulation. Median circuit survival increased with 
at least 165% when the combination of regional citrate anticoagula-
tion with either continuous IV heparin or therapeutic dose nadroparin 
was applied.
Conclusions: Continuous renal replacement therapy circuit patency 
is diminished in coronavirus disease 2019 ICU patients. Combining 
regional citrate anticoagulation with either continuous IV heparin or 
therapeutic dose nadroparin increases filter survival as compared 
with regional citrate anticoagulation alone in this nonrandomized 
observational study.
Key Words: acute kidney injury; anticoagulation; continuous renal 
replacement therapy; coronavirus disease 2019; critically ill
The spread of the 2019 novel coronavirus (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2]) throughout the world is a massive challenge for critical 
care facilities worldwide. While severe hypoxic respiratory failure 
is a key feature, a substantial proportion of patients with coronavi-
rus disease 2019 (COVID-19) on the ICU also need renal replace-
ment therapy (RRT) with reported incidences ranging from 5.6% 
to 61% (1). We initially observed remarkably short filter survival 
times due to frequent clotting of the extracorporeal circuit in the 
first patient with COVID-19 on continuous RRT (CRRT) in our 
center in March 2020. At that time, we received similar observa-
tions from colleagues in Italy, Spain, and the Netherlands. In a 
French multicenter prospective ICU study on thrombosis risk in 
patients with COVID-19, a shorter median lifespan of the CRRT 
circuit was observed in 28 of 29 patients (96.6%) and the total num-
ber of used CRRT circuits per patient was higher in COVID-19 
patients (2). Achieving adequate CRRT circuit survival times is 
highly relevant to avoid shortages in disposables (3, 4). Here we 
describe our experiences with CRRT in the first cohort of patients 
with COVID-19 in our ICU, and we compare filter survival using 
different methods of circuit anticoagulation.
MATERIALS AND METHODS
All consecutive COVID-19 patients during the first Netherlands 
COVID-19 peak, who were admitted to the ICU of our tertiary 
care academic teaching hospital between March 19, 2020, and 
May 18, 2020, were included in this descriptive study. The local 
Medical Ethics Review Board reviewed and waived (M20.252810) 
this study. All patients received increased thrombosis prophylaxis 
with subcutaneous nadroparin 5,700 international units (IUs) 
once daily, or a therapeutic dose when indicated.
CRRT was performed using Prismaflex (Baxter, Lund, Sweden) 
and Prismax (Baxter, Brooklyn Park, MN) systems with Prismaflex 
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ST 150 filterset (Baxter, Meyzieu Cedex, France) with a blood flow 
of 170–210 mL/min and an ultrafiltration rate of 30–47 mL/kg/hr. 
Venous access was obtained with a double-lumen 13F cen-
tral venous catheter (high-flow double-lumen catheter; Baxter, 
Hechingen, Germany). Prior to being connected to the patient, 
the CRRT circuit was primed with 10.000 IU heparin (Leo Pharma 
BV, Amsterdam, The Netherlands). Regional citrate anticoagula-
tion (RCA) was used as the first line anticoagulation modality, 
according to the Kidney Disease: Improving Global Outcomes 
Clinical Practice Guidelines for Acute Kidney Injury (AKI) (5), 
with a citrate concentration of 2.2 mmol/L. When no coagulation 
occurred, the CRRT circuit was replaced after reaching a lifespan 
of 72 hours. In patients who were already treated with therapeu-
tic subcutaneous doses of nadroparin, nadroparin treatment was 
continued during CRRT with RCA. If filter lifespan was shorter 
than 24 hours in patients who were not treated with therapeutic 
doses of nadroparin, a switch was made from RCA to continu-
ous IV heparin administration at the arterial side of the circuit 
with a target activated partial thromboplastin time (APTT) of less 
than 45 seconds. When persistent short circuit survival times were 
observed with this anticoagulation protocol, a target APTT of 45–
55 seconds was applied in subsequent CRRT sessions. When filter 
lifespan remained less than 24 hours, we combined RCA with con-
tinuous IV heparin administration.
Filter lifespans with different types of anticoagulation are given 
as a median with interquartile range (IQR) and were compared 
with Mann-Whitney U test. The same test was used for the com-
parison of the filter lifespan between patients with COVID-19 and 
a recent cohort of 20 non-COVID-19 patients.
RESULTS
A total of 101 patients with COVID-19 were treated in our ICU, 
of whom 11 patients required CRRT for a total of 127 CRRT days. 
Patient characteristics are shown in Table S1 (http://links.lww.
com/CCX/A384).
Standard RCA and continuous IV heparin anticoagulation 
were applied in eight and 12 circuits, respectively. Combined RCA 
with continuous heparin or therapeutic nadroparin administra-
tion was used in 46 and 24 circuits, respectively.
Anticoagulation with RCA or continuous IV heparin 
alone resulted in a median circuit patency of 10.7 hours (IQR, 
5.6–16.3 hr) and 11.4 hours (IQR, 7.5–14.0 hr), respectively 
(Fig. 1). In contrast, the median circuit survival times in our cen-
ter in 20 recent non-COVID-19 ICU patients treated with CRRT 
with RCA or continuous IV heparin were 37.8 hours (IQR, 22.1–
64.8 hr; p < 0.0001 compared with COVID-19 patients) and 66.5 
hours (IQR, 27.4–71.1 hr; p < 0.0001 compared with COVID-19 
patients), respectively.
The combination of RCA with either continuous IV heparin or 
therapeutic nadroparin administration resulted in longer median 
circuit survival times of 27.2 hours (IQR, 16.7–61.3 hr) and 18.75 
hours (IQR, 8.7–35.1 hr), respectively (compared to RCA alone 
p = 0.0007 and p = 0.072, respectively). Between patients that were 
treated with the combination of RCA and continuous IV hepa-
rin, there was no difference in filter survival time during APTT 
less than 45 seconds (median 34.3 hr, IQR 18.8–72.4) versus an 
APTT range of 45–55 seconds (median 27.2 hr, IQR 16.4–59.6) 
(p = 0.47). Filter survival during circuit anticoagulation with con-
tinuous IV heparin alone did also not increase with the applica-
tion of a higher APTT range of 45–55 seconds (median 11.5 hr, 
IQR 8.3–13.2) versus an APTT less than 45 seconds (7.5 hr, IQR 
3.3–16.8) (p = 0.56).
Bleeding complications were observed in two out of 11 patients 
during combined treatment with RCA and heparin, both with a 
target APTT range of 45–55 seconds. One patient suffered from 
bleeding lesions in the gastric cardia, and one patient suffered 
from intracerebral hemorrhage in the pons and thalamus which 
might be due to an episode of severe hypertension prior to the 
start of CRRT.
DISCUSSION
The major finding of this observational cohort study was that 
CRRT circuit patency in all ICU patients with COVID-19 was 
shorter than 24 hours using either standard RCA or continuous 
heparin treatment. Combining RCA with continuous heparin 
or therapeutic nadroparin administration increased the median 
circuit survival with at least 165%. A higher target APTT range 
during heparin treatment with or without RCA did not result in a 
longer filter lifespan as compared with a target APTT of less than 
45 seconds.
Recent data suggest that ICU patients with COVID-19 have 
an increased risk of thromboembolic events (2). This COVID-19 
associated coagulopathy is characterized by increased levels of 
fibrinogen and d-dimer (6) and may contribute to the decreased 
CRRT circuit survival times (2).
Our clinical observations suggest that RCA and heparin treat-
ment alone are insufficient to prevent coagulation in the CRRT 
circuit in COVID-19 patients. However, since the number of 
CRRT circuits per anticoagulation modality in this report is lim-
ited, we still advise standard RCA as the initial anticoagulation 
modality. In case circuit survival is shorter than 24 hours, we sug-
gest to combine RCA with continuous IV heparin administration. 
Figure 1. Filter survival. Median circuit patency’s. Error bars indicate median 
and interquartile. RCA = regional citrate anticoagulation.
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Because of a potentially increased risk of bleeding and lack of lon-
ger circuit survival times at higher APTT target ranges, we suggest 
to use a target APTT less than 45 seconds when using heparin (7). 
In patients who have an indication for therapeutic low-molecular-
weight heparin treatment, we suggest to combine this systemic 
anticoagulation treatment with RCA. In case of contraindications 
for RCA, we propose to start continuous replacement therapy with 
heparin anticoagulation and, when circuit survival is shorter than 
24 hours, switch to intermittent hemodialysis since most patients 
with COVID-19 in the ICU are hemodynamically stable.
Our report has several limitations. First, we included the whole 
first COVID-19 wave in our observational study, but still have a 
relatively low number of patients. Second, as we describe our clini-
cal process to optimize filter survival in AKI COVID-19 patients, 
our study had a nonrandomized, nonblinded observational char-
acter. Third, we analyzed a low number of covariates. Despite 
these limitations, our study is the largest series of patients with 
COVID-19 with detailed description of circuit survival time com-
paring different modes of anticoagulation. Thus, we chose to share 
our experiences already in this early stage in order to contribute 
to optimization of CRRT treatment in patients with COVID-19 
including the prevention of shortages in CRRT filtersets in ICUs 
confronted with the 2019 novel coronavirus SARS-CoV-2. Future 
larger randomized trials should study the best anticoagulation 
regimen for CRRT in critically ill COVID-19 patients with AKI.
CONCLUSIONS
CRRT circuit patency is diminished in COVID-19 ICU patients. 
The combination of RCA with either continuous IV heparin or 
therapeutic dose nadroparin increased filter survival as compared 
with RCA alone. The efficacy and safety of these anticoagulation 
regimens should be confirmed in larger studies.
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